Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,096.00
Bid: 12,088.00
Ask: 12,092.00
Change: 0.00 (0.00%)
Spread: 4.00 (0.033%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,096.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Stocks make headway amid weak China data

Mon, 15th Aug 2022 17:00

(Alliance News) - Stocks in London struggled on Monday, but managed to end higher, even as China's central bank slashed key interest rates as a raft of data showed weakness in the world's second-largest economy.

The PBoC on Monday sliced the medium-term lending rate to 2.75%, a reduction of 10 basis points. The interest rate is used a benchmark for one-year loans provided to the banking system.

The move came after factory output and retail sales in China edged up in July but were weaker than analysts' expectations, as a Covid-19 resurgence and property market jitters cast a pall over hopes for a stronger economic recovery.

The world's second-biggest economy saw a bounce in business activity as some coronavirus restrictions eased in June, but the boost is fading and Beijing remains welded to a zero-Covid policy of snap lockdowns and long quarantines, which has battered sentiment.

But for July, China's industrial production rose 3.8% on-year, down from a 3.9% jump in June, the National Bureau of Statistics said Monday. This undershot market expectations, cited by FXStreet, for growth to speed up to 4.6%.

Retail sales grew at a slower-than-expected 2.7% from a year ago, down from 3.1% in June, while the urban unemployment rate fell to 5.4%, the NBS said. Retail sales had been expected to rise 5%, cited by FXStreet.

The FTSE 100 index closed up 8.26 points, or 0.1%, at 7,509.15. The FTSE 250 closed up 43.80 points, or 0.2%, at 20,382.76, and the AIM All-Share closed up 0.91 of a point at 934.11.

The Cboe UK 100 ended up 0.1% at 749.94. The Cboe UK 250 closed down 0.1% at 17,684.28. The Cboe Small Companies ended flat at 14,472.95.

In European equities, the CAC 40 in Paris ended up 0.3%, while the DAX 40 in Frankfurt ended up 0.2%.

CMC Markets analyst Michael Hewson said: "Basic resources and energy sector have borne the brunt of today's uncertainty after [China's] July industrial production and retail sales both came in well below expectations. The bigger surprise is why anyone is surprised by this given China's reluctance to relax its zero-covid policy, a policy that is likely to weigh on economic growth even more as we head into the winter months.

"As the weather gets colder it's unlikely that infection rates will go down, which means economic activity is likely to remain subdued, and consumer demand will remain weak. In response to today's data China's central bank cut its medium-term lending rate by 10bps, to 2.75%, in a vain attempt to stimulate demand."

In the FTSE 100, RS Group ended the best performer, up 5.0% at 1,142.38 pence, after the Times reported at the weekend that the electrical parts maker could be the subject of a takeover bid.

The Times reported that there has been "chat" that there may be a GBP15-a-share bid imminently. This would be a significant premium to the present price and above the GBP12.35 high the company, formerly known as Electrocomponents, hit last November before worries about recession surfaced.

However, the report did not name any potential suitor.

AstraZeneca closed up 2.2% after it said, alongside partner Daiichi Sankyo, that their Enhertu drug met its primary endpoint in a breast cancer trial.

The Cambridge-based pharmaceutical firm said a form of breast cancer in patients treated with Enhertu showed slowed disease progression. The trial involved sufferers of human epidermal growth factor receptor 2-positive unresectable and/or metastatic breast cancer. Participants had been previously treated with trastuzumab emtansine, an existing cancer therapy.

At the other end of the large-caps, miners were among the worst performers following the disappointing China data. Antofagasta closed down 1.5%, Anglo American down 2.4%, Rio Tinto down 2.2% and Glencore down 1.4%.

Meanwhile, Rio Tinto reiterated its proposal to acquire full-ownership of Turquoise Hill Resources for CAD34 per share, around USD25.48.

The announcement comes after Turquoise Hill said earlier in the day that it was no longer considering Rio Tinto's takeover offer. The Canadian miner said Rio Tinto's offer did not "fully and fairly reflect the fundamental and long-term strategic value" of its majority ownership in the Oyu Tolgoi copper-gold project in Mongolia.

As a result, the company said it was not in the best interest of the company or its shareholders to support Rio Tinto's proposal. Rio Tinto said it was "disappointed" by the decision and asserted that the terms of its proposal would deliver "compelling value" for Turquoise Hill.

In March, the FTSE 100-listed miner announced it was proposing to acquire the remaining 49% of Turquoise Hill that it does not currently own. This represented a 32% premium to the firm's closing price on the Toronto Stock Exchange at the time.

Oil majors BP and Shell closed down 1.2% and 1.5% respectively, tracking spot oil prices lower.

Brent oil was quoted at USD94.22 a barrel at the equities close, down sharply from USD97.91 at the close Friday.

In the FTSE 250, Auction Technology ended the worst performer, down 4.7%, after JPMorgan downgraded the platform to 'neutral' from 'overweight'.

The pound was quoted at USD1.2075 at the London equities close, down from USD1.2121 at the close Friday.

The euro stood at USD1.0184 at the European equities close, down from USD1.0248. Against the yen, the dollar was trading at JPY133.07, down from JPY133.63.

Stocks in New York were lower at the London equities close. The DJIA was down 0.1%, the S&P 500 index down 0.3% and the Nasdaq Composite down 0.2%.

On Wall Street, Moderna was up 2.5% after the UK's medicines regulator said it had approved an updated version of the drugmaker's vaccine against Covid-19, that targets the Omicron variant as well as the original form of the virus.

The Medicine & Healthcare products Regulatory Agency said it had approved the vaccine for adult booster doses "after it was found to meet the UK regulator's standards of safety, quality and effectiveness".

It was the first such "bivalent" Covid-19 vaccine to be approved by the UK regulator.

Gold stood at USD1,778.71 an ounce at the London equities close, lower against USD1,797.13 late Friday.

The economic events calendar on Tuesday has UK unemployment data at 0700 BST and Germany ZEW indicator of economic sentiment at 1000 BST.

The UK corporate calendar on Tuesday has annual results from miner BHP Group and interim results from Bank of Georgia. Authorised Rolex dealer Watches of Switzerland puts out first-quarter numbers.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more
26 Feb 2024 07:22

AstraZeneca's blood-disorder drug recommended for EU approval

(Sharecast News) - European regulators has given the green light to AstraZeneca's blood-disorder drug Voydeya, the biopharma giant announced on Monday.

Read more
22 Feb 2024 17:36

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

Read more
20 Feb 2024 10:29

AstraZeneca acquires US-based biopharmaceutical company

(Sharecast News) - Drugmaker AstraZeneca revealed late on Monday afternoon that it had successfully completed its acquisition of US-based biopharmaceutical company Icosavax.

Read more
20 Feb 2024 09:40

LONDON BROKER RATINGS: JPMorgan cuts Airtel Africa price target by 28%

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
19 Feb 2024 16:51

LONDON MARKET CLOSE: Europe lacks direction on quiet Monday

(Alliance News) - European markets lacked direction on Monday, after a quiet day as the US markets celebrated George Washington's birthday.

Read more
19 Feb 2024 15:59

London close: Stocks manage gains on globally quiet day

(Sharecast News) - London's financial markets finished in positive territory on Monday, with stocks closing in the green after overcoming minor losses earlier in the session.

Read more
19 Feb 2024 15:39

UPDATE: AstraZeneca completes USD1.1 billion acquisition of Icosavax

(Alliance News) - AstraZeneca PLC on Monday said it has completed the acquisition of Icosavax Inc.

Read more
19 Feb 2024 11:51

LONDON MARKET MIDDAY: Stocks lack direction amid quiet start to week

(Alliance News) - Stock prices in London lacked direction at midday Monday, amid a quiet start to the week.

Read more
19 Feb 2024 08:44

LONDON MARKET OPEN: Stocks drift; Currys surges on takeover interest

(Alliance News) - Stock prices in London were looking for direction early Monday, as investors weighed possible trajectories for US interest rate cuts and a China's economic recovery.

Read more
19 Feb 2024 08:36

TOP NEWS: AstraZeneca celebrates Tagrisso approval and new data

(Alliance News) - AstraZeneca PLC on Monday announced new study data and a new approval for its cancer medication Tagrisso.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.